Maria Psyllaki

547 total citations
22 papers, 436 citations indexed

About

Maria Psyllaki is a scholar working on Hematology, Immunology and Genetics. According to data from OpenAlex, Maria Psyllaki has authored 22 papers receiving a total of 436 indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Hematology, 7 papers in Immunology and 6 papers in Genetics. Recurrent topics in Maria Psyllaki's work include Acute Myeloid Leukemia Research (7 papers), Blood disorders and treatments (6 papers) and Immunodeficiency and Autoimmune Disorders (3 papers). Maria Psyllaki is often cited by papers focused on Acute Myeloid Leukemia Research (7 papers), Blood disorders and treatments (6 papers) and Immunodeficiency and Autoimmune Disorders (3 papers). Maria Psyllaki collaborates with scholars based in Greece, United Kingdom and United States. Maria Psyllaki's co-authors include Helen Α. Papadaki, Charalampos Pontikoglou, George D. Eliopoulos, Rachel Jakubiak, Spiros H. Anastasiadis, Emmanuel P. Giannelis, Giannis Zacharakis, Rabindra Nath Das, Irene Mavroudi and Andreas Stassinopoulos and has published in prestigious journals such as Blood, Clinical Cancer Research and British Journal of Haematology.

In The Last Decade

Maria Psyllaki

22 papers receiving 427 citations

Peers

Maria Psyllaki
Hyoeun Shim South Korea
Timo Weiß Germany
Martin Sorette United States
K Kawano Japan
Rick Huisjes Netherlands
Emily C. Liang United States
Maria Psyllaki
Citations per year, relative to Maria Psyllaki Maria Psyllaki (= 1×) peers Xiaofei Yang

Countries citing papers authored by Maria Psyllaki

Since Specialization
Citations

This map shows the geographic impact of Maria Psyllaki's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Maria Psyllaki with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Maria Psyllaki more than expected).

Fields of papers citing papers by Maria Psyllaki

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Maria Psyllaki. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Maria Psyllaki. The network helps show where Maria Psyllaki may publish in the future.

Co-authorship network of co-authors of Maria Psyllaki

This figure shows the co-authorship network connecting the top 25 collaborators of Maria Psyllaki. A scholar is included among the top collaborators of Maria Psyllaki based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Maria Psyllaki. Maria Psyllaki is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Ιωάννου, Πέτρος, Evangelia Akoumianaki, Maria Psyllaki, et al.. (2020). Hemophagocytic lymphohistiocytosis syndrome associated with Epstein-Barr infection in an omnicompetent patient. A case study. GERMS. 10(3). 266–271. 2 indexed citations
2.
Samonakis, Dimitrios, Maria Psyllaki, Ηλίας Δράκος, et al.. (2019). Aggressive recurrence of Non-Hodgkin's Lymphoma after successful clearance of hepatitis C virus with direct acting antivirals. Annals of Hepatology. 21. 100141–100141. 4 indexed citations
4.
Velegraki, Maria, Evangelia A. Papakonstanti, Irene Mavroudi, et al.. (2013). Impaired clearance of apoptotic cells leads to HMGB1 release in the bone marrow of patients with myelodysplastic syndromes and induces TLR4-mediated cytokine production. Haematologica. 98(8). 1206–1215. 51 indexed citations
5.
Symeonidis, Argiris, Panagiotis Zikos, Athanasios Galanopoulos, et al.. (2011). 319 Response to treatment with erythropoietin in patients with MDS highly predicts low risk of evolution to AML and longer survival. Leukemia Research. 35. S127–S128. 2 indexed citations
6.
Kastrinaki, Maria-Christina, Aristea Batsali, Maria Velegraki, et al.. (2011). Impaired Wnt-Pathway Signalling and Reduced Expression of Senescence-Associated Markers in Bone Marrow Mesenchymal Stem Cells of Patients with Myelodysplastic Syndromes. Blood. 118(21). 272–272. 4 indexed citations
7.
Mavroudi, Irene, Katerina Pyrovolaki, Maria Psyllaki, et al.. (2010). Effect of the nonpeptide thrombopoietin receptor agonist eltrombopag on megakaryopoiesis of patients with lower risk myelodysplastic syndrome. Leukemia Research. 35(3). 323–328. 31 indexed citations
8.
Klaus, Mirjam, Maria-Christina Kastrinaki, Krinio Giannikou, et al.. (2009). Reserves, Functional, Immunoregulatory, and Cytogenetic Properties of Bone Marrow Mesenchymal Stem Cells in Patients with Myelodysplastic Syndromes. Stem Cells and Development. 19(7). 1043–1054. 55 indexed citations
9.
Galanopoulos, Athanasios, Agapi Parcharidou, Krinio Giannikou, et al.. (2009). Effect of lenalidomide therapy on hematopoiesis of patients with myelodysplastic syndrome associated with chromosome 5q deletion. Haematologica. 95(3). 406–414. 36 indexed citations
10.
Symeonidis, Argiris, Alexandra Kouraklis‐Symeonidis, Panagiotis Zikos, et al.. (2007). P140 Factors predicting for a favorable response among patients with myelodysplastic syndromes treated with erythropoietin ± G-CSF. Leukemia Research. 31. S116–S117. 2 indexed citations
11.
Voulgarelis, Michael, Stavroula Giannouli, Maria Psyllaki, et al.. (2006). Effect of cA2 Anti–Tumor Necrosis Factor-α Antibody Therapy on Hematopoiesis of Patients with Myelodysplastic Syndromes. Clinical Cancer Research. 12(10). 3099–3108. 21 indexed citations
12.
Psyllaki, Maria, et al.. (2005). Neurofibromatosis type I and smoldering multiple myeloma: A case report. Hematology. 11(1). 45–48. 1 indexed citations
13.
Papadaki, Helen Α., Christos Tsatsanis, Anna Christoforidou, et al.. (2004). Alendronate reduces serum TNF? and IL-1?, increases neutrophil counts, and improves bone mineral density and bone metabolism indices in patients with chronic idiopathic neutropenia (CIN)-associated osteopenia/osteoporosis. Journal of Bone and Mineral Metabolism. 22(6). 577–587. 27 indexed citations
14.
Czoski‐Murray, Carolyn, Emma Warren, J. Chilcott, et al.. (2004). Clinical effectiveness and cost-effectiveness of pioglitazone and rosiglitazone in the treatment of type 2 diabetes: a systematic review and economic evaluation. Health Technology Assessment. 8(13). iii, ix–x, 1. 38 indexed citations
15.
Papadaki, Helen Α., Panagiotis Skordilis, George Minadakis, et al.. (2003). Complete regression of primary gastric plasmacytoma following Helicobacter pylori eradication. Annals of Hematology. 82(9). 589–592. 18 indexed citations
16.
Giannelis, Emmanuel P., Maria Psyllaki, Giannis Zacharakis, et al.. (2002). Random Lasers Based on Organic-Inorganic Hybrids. MRS Proceedings. 726. 2 indexed citations
17.
Papadaki, Helen Α., et al.. (2001). Increased Frequency and Specific Reactivity of Serum Antinuclear Antibodies in Patients with Nonimmune Chronic Idiopathic Neutropenia of Adults. Acta Haematologica. 105(1). 13–20. 5 indexed citations
18.
Papadaki, Helen Α., Frances M. Gibson, Maria Psyllaki, et al.. (2001). Assessment of bone marrow stem cell reserve and function and stromal cell function in patients with severe congenital neutropenia. European Journal Of Haematology. 67(4). 245–251. 9 indexed citations
19.
Papadaki, Helen Α., et al.. (2001). Patients with non-immune chronic idiopathic neutropenia syndrome have increased splenic volume on ultrasonography. Clinical & Laboratory Haematology. 23(2). 111–117. 10 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026